Is more than one application of an antifungal necessary in the treatment of acute vaginal candidiasis?
The results of all the controlled trials carried out at the Department of Genito-Urinary Medicine at the Cardiff Royal Infirmary over the past 16 years are summarized. All except one of these trials were carried out with patients having acute vulvovaginal candidiasis. One trial involved treating only patients with recurring candidal infection. In all the acute trials, there were practically no mycologic relapses 7 days after completion of treatment whatever the regimen used, but at 35 days after completion of treatment the mycologic relapse rate was in the region of 20% to 25%. It is concluded that following the elimination of any known predisposing cause of vaginal candidiasis, the intravaginal application of 500 mg of an imidazole preparation is as effective a treatment as any other regimen. In recurrent cases, monthly treatment with such a dose may be adequate to control the patient's symptoms. Mycologic relapse may not be accompanied by symptoms, but in recurrent cases there is a closer relation between mycologic relapse and symptoms.